Active Ingredient: FENOFIBRATE
(Hérité de FENOFIBRATE ALMUS 160 mg) Conflicting data: While in vitro inhibition of KCNQ1 potassium currents suggests a theoretical risk, no QT prolongation has been reported in clinical practice. Animal models of heart failure even suggest a cardioprotective effect with improvement of ECG abnormalities.
https://doi.org/10.1177/0960327119860173, https://doi.org/10.1152/ajpgi.00234.2007, https://doi.org/10.5114/pdia.2014.43191